Cipla – Inventory Write-Off Impacts Q4, Progress On Inhalation Assets Key Driver: Dolat Capital

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Cipla Ltd.’s Q4 missed estimates as company took one-time shelf stock adjustment for Albuterol based on competitors’ entry.

The impact was 2%, adjusting for which Ebitda margins are in line at 19-20%.

While U.S. sales at $138 million were sequentially flattish, impacted by seasonality, price erosion in the base portfolio, the company’s profitability in the U.S. is now equivalent to company’s level.

Management remains confident of gaining further market share in Albuterol (has 87% prescription within Proventil market).

Further, management guided that it has strong visibility of product launches in the U.S. in FY22E to sustain growth.

Click on the attachment to read the full report:

Dolat Capital Cipla Q4FY21 Result Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Most Related Links :
verity news now Governmental News Finance News

Source link

Back to top button